Hypersensitivity Reactions and Gout Tx: Watch the Dose

Save

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

NSAID Safety Guidelines

Save

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complica

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Save

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

Save

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Save

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

RheumNow Podcast - The Elusive Hand OA Problem (12.13.19)

Save

Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Save

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.

ACR 2019 - Report From Day 2 (Monday)

Save

Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.

The Safety of Methotrexate

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Save

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

T2T Lowers Mortality in Gout

Save

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Save

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Patients Prefer Nurse Led Care for their Gout

Save

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level 6 mg/dl, this goal is seldom achieved ( 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)

Save

Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Women Take Over Rheumatology (10.4.19)

Save

Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.

Anakinra Use in Hospitalized Gout Patients

Save

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)

Save

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.